四神丸联合美沙拉嗪治疗溃疡性结肠炎48例临床观察

Clinical Observation of Sishen Pill Combined with Mesalazine in Treatment of 48 Cases of Ulcerative Colitis

目的:探讨四神丸联合美沙拉嗪治疗溃疡性结肠炎的临床疗效。方法:选取2022年1月至2023年7月,本院治疗的96例溃疡性结肠炎患者。随机分为观察组和对照组,每组各48例。对照组口服美沙拉嗪肠溶片治疗,观察组在对照组基础上联合四神丸口服治疗。比较2组临床疗效,肠道菌群和临床症状等情况。结果:治疗后,观察组大肠杆菌和肠球菌数量显著低于对照组(P<0.05),乳酸杆菌和双歧杆菌数量显著高于对照组(P<0.05),临床症状积分显著低于对照组(P<0.05)。结论:四神丸联合美沙拉嗪治疗溃疡性结肠炎临床效果良好,可明显改善患者肠道菌群,减轻临床症状。

Objective To explore the clinical efficacy of Sishen Pill combined with mesalazine in the treatment of ulcerative colitis.Methods Total 96 patients with ulcerative colitis treated in our hospital from January 2022 to July 2023 were selected and randomly divided into observation group and control group,with 48 cases in each group.The control group was given mesalazine enteric-coated tablets,and the observation group was treated with Sishen Pill on the basis of the control group.The clinical efficacy,intestinal flora and clinical symptoms of the two groups were compared.Results After treatment,the number of Escherichia coli and enterococcus in the observation group was significantly lower than that in the control group(P<0.05).The number of lactobacillus and bifidobacterium was significantly higher than that in the control group(P<0.05),and the clinical symptom score was significantly lower than that in the control group(P<0.05).Conclusion Sishen Pill combined with mesalazine has good clinical effect in the treatment of ulcerative colitis,which can obviously improve the intestinal flora of patients and alleviate the clinical symptoms.